METHOD FOR PREDICTION OF EFFECTIVENESS OF NEOADJUVANT AUTOMYELOCHEMOTHERAPY IN PATIENTS WITH RECURRENT BREAST CANCER

摘要

FIELD: medicine.;SUBSTANCE: prior to begin the therapy, the patient's blood is tested for oestradiol concentration. If the concentration is 18.40 to 29.40 nmol/l, tumour size loss after the neoadjuvant automyelochemotherapy by 67-70% is predicted, that is a partial regress of the tumour, while oestradiol concentration 208.50 to 1541.0 nmol/l enables to predict the tumour size loss by 5-45% that is process stabilisation.;EFFECT: use of the invention allows determining sensitivity of the recurrent breast cancer to the neoadjuvant automyelochemotherapy for an individual correction of treatment policy in patients with said pathology.;1 tbl, 3 ex